» Articles » PMID: 35163478

Different Expression Levels of DLK2 Inhibit NOTCH Signaling and Inversely Modulate MDA-MB-231 Breast Cancer Tumor Growth In Vivo

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2022 Feb 15
PMID 35163478
Authors
Affiliations
Soon will be listed here.
Abstract

NOTCH signaling is implicated in the development of breast cancer tumors. DLK2, a non-canonical inhibitor of NOTCH signaling, was previously shown to be involved in skin and breast cancer. In this work, we studied whether different levels of DLK2 expression influenced the breast cancer characteristics of MDA-MB-231 cells. We found that DLK2 overexpression inhibited NOTCH activation in a dose-dependent manner. Moreover, depending on the level of inhibition of NOTCH1 activation generated by different levels of DLK2 expression, cell proliferation, cell cycle dynamics, cell apoptosis, cell migration, and tumor growth in vivo were affected in opposite directions. Low levels of DLK2 expression produced a slight inhibition of NOTCH1 activation, and enhanced MDA-MB-231 cell invasion in vitro and cell proliferation both in vitro and in vivo. In contrast, MDA-MB-231 cells expressing elevated levels of DLK2 showed a strong inhibition of NOTCH1 activation, decreased cell proliferation, increased cell apoptosis, and were unable to generate tumors in vivo. In addition, DLK2 expression levels also affected some members of other cell signaling pathways implicated in cancer, such as ERK1/2 MAPK, AKT, and rpS6 kinases. Our data support an important role of DLK2 as a protein that can finely regulate NOTCH signaling and affect the tumor properties and growth dynamics of MDA-MB-231 breast cancer cells.

Citing Articles

DLK1 and DLK2, two non-canonical ligands of NOTCH receptors, differentially modulate the osteogenic differentiation of mesenchymal C3H10T1/2 cells.

Rodriguez-Cano M, Gonzalez-Gomez M, Monsalve E, Diaz-Guerra M, Kassem M, Laborda J Biol Res. 2024; 57(1):77.

PMID: 39473022 PMC: 11523663. DOI: 10.1186/s40659-024-00561-7.


Serum CD133-Associated Proteins Identified by Machine Learning Are Connected to Neural Development, Cancer Pathways, and 12-Month Survival in Glioblastoma.

Joyce T, Tasci E, Jagasia S, Shephard J, Chappidi S, Zhuge Y Cancers (Basel). 2024; 16(15).

PMID: 39123468 PMC: 11311306. DOI: 10.3390/cancers16152740.


Exploring the molecular mechanism of glycyrrhetinic acid in the treatment of gastric cancer based on network pharmacology and experimental validation.

Li X, Du Y, Huang S, Yang Y, Lu D, Zhang J Aging (Albany NY). 2023; 15(9):3839-3856.

PMID: 37171392 PMC: 10449304. DOI: 10.18632/aging.204718.

References
1.
Wang X, Song N, Zhang Y, Cai Y, Liu Y, Qu X . Coexpression of c-Met and Notch-1 correlates with poor prognosis in resected non-small-cell lung cancer. Tumour Biol. 2015; 36(9):7053-9. DOI: 10.1007/s13277-015-3404-4. View

2.
Huang Z, Yu P, Tang J . Characterization of Triple-Negative Breast Cancer MDA-MB-231 Cell Spheroid Model. Onco Targets Ther. 2020; 13:5395-5405. PMC: 7295545. DOI: 10.2147/OTT.S249756. View

3.
Chen L, Qanie D, Jafari A, Taipaleenmaki H, Jensen C, Saamanen A . Delta-like 1/fetal antigen-1 (Dlk1/FA1) is a novel regulator of chondrogenic cell differentiation via inhibition of the Akt kinase-dependent pathway. J Biol Chem. 2011; 286(37):32140-9. PMC: 3173234. DOI: 10.1074/jbc.M111.230110. View

4.
Nueda M, Gonzalez-Gomez M, Rodriguez-Cano M, Monsalve E, Diaz-Guerra M, Sanchez-Solana B . DLK proteins modulate NOTCH signaling to influence a brown or white 3T3-L1 adipocyte fate. Sci Rep. 2018; 8(1):16923. PMC: 6240076. DOI: 10.1038/s41598-018-35252-3. View

5.
Kumar A, White T, MacKenzie A, Clegg N, Lee C, Dumpit R . Exome sequencing identifies a spectrum of mutation frequencies in advanced and lethal prostate cancers. Proc Natl Acad Sci U S A. 2011; 108(41):17087-92. PMC: 3193229. DOI: 10.1073/pnas.1108745108. View